Infant Bacterial Therapeutics ABOMXSTO: IBT_B

Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3

Oct 3, 2025 at 12:08 PM EDT · Issued by Infant Bacterial Therapeutics AB

On 6ix: 6ix.com/news/infant-bacterial-therapeutics-ab-quarterly-trading-report-2025-q3

Nordic ListingsIssuer Report

Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=b106cab94dfa921bcda88dfee0b0b6bb0&lang=en&src=omxlink

Infant Bacterial Therapeutics AB on 6ix

Earlier from Infant Bacterial Therapeutics

IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensifyAug 20, 2025
IBT_B: FDA Breakthrough Therapy Designation for IBP-9414 accelerates IBT's market pathMay 7, 2025
IBT_B: IBP-9414's Phase 3 trial showed 27% lower mortality; BLA submission planned for 2025Feb 13, 2025
IBT_B: Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory pushNov 14, 2024
IBT_B: Significant 27% mortality reduction observed in preterm infants, despite missed primary endpointsSep 3, 2024

Later from Infant Bacterial Therapeutics

Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 MlnNov 13, 2025
Infant Bacterial Therapeutics Secures Partnership For Production Of Drug SubstanceNov 20, 2025
Infant Bacterial Therapeutics Secures Partnership For Production Of Drug ProductDec 12, 2025
Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 MlnFeb 6
Infant Bacterial Announces Phase III IBP-9414 Study ResultsMar 3

All Infant Bacterial Therapeutics news releases

Follow Infant Bacterial Therapeutics into a list and get an email when it puts out news.

Follow Infant Bacterial Therapeutics